ALIA-1758

Product Description

High-affinity 3pE-Aβ binders enable lower predicted efficacious dosage levels compared to competitors, and target the plaque form of Aβ rather than earlier stages of aggregationAn optimized Fc domain increases half-life, reduces effector function and leads to clearance of bound antibodies through a mechanism that reduces pro-inflammatory cytokine release and immune exhaustion (see "Novel antibody clearance mechanism" below).The anti-TfR Delivery Module transports 3pE-Aβ antibodies into the brain at a higher concentration than naked antibodies, leading to more efficient target clearance. The proprietary scFv design also confers increased stability, reduced aggregation and lower manufacturing cost. Aliada’s ALIA-1758 has the potential to be a best-in-class therapy for the treatment of patients with Alzheimer’s disease (AD). MODEL platform-enabled by Aliada to harness transport via TfR, ALIA-1758’s strong target binder properties and improved CNS delivery offers the potential to achieve robust reduction of brain amyloid burden at lower dosage levels than other antibodies in this class. Consequently, a convenient monthly subcutaneous low-dose regimen could improve access to therapy for more patients with AD. A high-value program in its own right, ALIA-1758’s advancement also provides an opportunity to establish clinical proof-of-principle for the MODEL platform. (Sourced from: https://aliadatx.com/programs/)

Mechanisms of Action: AB Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Aliada Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None